Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

Slides:



Advertisements
Similar presentations
Mandal CC et al Supplementary Fig. S1. Increased expression of CSF-1 in human breast cancer cells. (A) The conditioned media from normal human breast epithelial.
Advertisements

PP1 and PP2A inhibitors rescue α-SMA expression and Akt phosphorylation from the inhibitory effects of TSA. After serum starvation, NHLFs were pretreated.
PI 3-kinase inhibition has no effect on ANG II induced extracellular recognition kinase (ERK) 1/2 activation. PI 3-kinase inhibition has no effect on ANG.
Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy  Dina Chelouche-Lev, Claudia P. Miller, Carmen.
Neal et al.Supplementary Figure S1
A B C MDA-MB-231 OHT: h FOXM1 PLK CDC25b ERα Tubulin
Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.
Inhibition of PDGFR-β downstream signaling events by flavones.
Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.
MET Tyrosine Kinase Inhibitor Crizotinib (PF ) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations 
PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation. PI3K isoform–selective inhibitors and PTEN induction decrease ERK phosphorylation.
Small-molecule inhibitor QLT-0267 suppresses ILK activity and inhibits its downstream signaling. Small-molecule inhibitor QLT-0267 suppresses ILK activity.
Inactivation of the MEK/ERK pathway in the myocardium during cardiopulmonary bypass  Eugenio G. Araujo, DVMa, b, Cesario Bianchi, MD, PhDa, Kaori Sato,
Proline supplementation during P5CS protein knockdown suppressed GCN2 activation. Proline supplementation during P5CS protein knockdown suppressed GCN2.
B. MAb 9E1 reduces MMP-9 activity in MDA-MB-231 cells. A
Ganglioside GM3 Promotes Carcinoma Cell Proliferation via Urokinase Plasminogen Activator-Induced Extracellular Signal-Regulated Kinase-Independent p70S6.
NF1 downregulation activates MAPK pathway signaling.
Volume 6, Issue 2, Pages (August 2004)
Monica Kong-Beltran, Jennifer Stamos, Dineli Wickramasinghe 
The Actin-Bundling Protein Palladin Is an Akt1-Specific Substrate that Regulates Breast Cancer Cell Migration  Y. Rebecca Chin, Alex Toker  Molecular.
Volume 54, Issue 5, Pages (June 2014)
p38 MAPK activation is required for phosphorylation of Akt at Ser473.
The role of SRC-C3G-RAP1 signaling in transformation induced by CRKL
Knocking down Wnt3 increases the cells' response to trastuzumab and reduces cells' invasiveness. Knocking down Wnt3 increases the cells' response to trastuzumab.
PTK6 downregulation suppresses SNAIL and increases E-cadherin expression. PTK6 downregulation suppresses SNAIL and increases E-cadherin expression. A,
Defective MEK-Erk1/2 kinase activation in RIAM-depleted cells accounts for their impaired FA disassembly. Defective MEK-Erk1/2 kinase activation in RIAM-depleted.
BEZ235 induces MAPK signaling in a FOXO3A-dependent manner.
eNOS regulated IR-induced NO generation and EGFR signal activation.
Role of Src and PTP-PEST in upregulation of tyrosine phosphorylation of paxillin and FAK. (A) Mock and D11 cells were pre-incubated with PP2 or PP3 (10 µM,
The dynamics of Akt activation in cultured human keratinocytes.
Curcumin-generated ROS activates Chk1 and Chk2 kinases.
PKM2 is tyrosine phosphorylated and inhibited by FGFR1 in cancer cells with oncogenic or overexpressed FGFR1. PKM2 is tyrosine phosphorylated and inhibited.
Figure 5. Effect of insulin-like growth factor 1 (IGF-1) induced extracellular regulated protein kinases 1/2 (ERK1/2) activation and the signal-responsive.
FOXO3a phosphorylation and expression.
Volume 2, Issue 2, Pages (August 2002)
AG1024 reduced the level of tyrosyl-phosphorylated proteins, including Erk2. AG1024 reduced the level of tyrosyl-phosphorylated proteins, including Erk2.
DNA damage signaling regulates mutant p53 ubiquitination.
Imatinib mesylate inhibits PDGF-mediated ERK and Akt activation.
Selective delivery of pIC/PPHAffibody decreases the survival of HER2-overexpressing cells. Selective delivery of pIC/PPHAffibody decreases the survival.
Geldanamycin-induced endocytosis and down-regulation of ErbB2 in cells expressing ErbB2 only. Geldanamycin-induced endocytosis and down-regulation of ErbB2.
The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.
CXCR4 expression levels of MDA-MB-231 cells at 48 hours posttransfection of CXCR4 siRNAs. CXCR4 expression levels of MDA-MB-231 cells at 48 hours posttransfection.
Effects of visfatin on the cell proliferation and phosphorylation of ERK, Akt, and GSK-3β proteins in HCC cells. Effects of visfatin on the cell proliferation.
Effect of other nucleoside analogues on p38 MAPK phosphorylation levels. Effect of other nucleoside analogues on p38 MAPK phosphorylation levels. A, MM.1S.
The expression of d-GM3 facilitates melanoma cell migration and invasion by activating p38 MAPK, not ERK. A, cell migration and invasion in d-GM3–positive.
Sample-wise outlier kinases in ERBB2-positive breast cancer cell lines
Expression of CRC stem cell markers and L1 in CRC cells.
MDA-468TR-PTEN (with and without 100 ng/ml doxycycline) and MDA-468TR-vector (with dox) were serum starved overnight and the following day treated for.
Activation of Wnt signaling pathway in trastuzumab-resistant cell lines. Activation of Wnt signaling pathway in trastuzumab-resistant cell lines. A, bar.
ERK reactivation following EGFR TKI treatment.
Expression of dominant-negative RasN17 completely suppresses Ras activation in Rh1 cells. Expression of dominant-negative RasN17 completely suppresses.
ABT-100 inhibits PI3K activity and p85 tyrosine phosphorylation.
Changes in signal transduction pathway induced by gefitinib.
Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors. Met is expressed in Her2-overexpressing cell lines and Her2 (+) breast tumors.
The Ser124 site of Cdc25A is required for Cdc25A degradation in response to I3C induction. The Ser124 site of Cdc25A is required for Cdc25A degradation.
The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. The combination of trastuzumab and SU11274 abrogate Akt phosphorylation. Serum-starved.
FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung cancer cell lines. FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung.
AS1411 alters subcellular distribution of PRMT5 in a time-dependent, dose-dependent, and nucleolin-dependent manner. AS1411 alters subcellular distribution.
BCR/ABL expression, tyrosine phosphorylation, and signaling in dasatinib- and imatinib-resistant cell lines and the ubiquitin inhibitor lactacystin modifies.
EGCG affects growth factor receptor signaling in H2111, H358, and H460 NSCLC cells. EGCG affects growth factor receptor signaling in H2111, H358, and H460.
CpG oligodeoxynucleotide (CpG ODN)–induced activation of different types of primary malignant B cells. CpG oligodeoxynucleotide (CpG ODN)–induced activation.
Posttranslational phosphorylation of p53 by platinum drugs in ovarian tumor cells. Posttranslational phosphorylation of p53 by platinum drugs in ovarian.
RRP1B interacts with TRIM28 and HP1α at regions associated with H3K9me3 and decreased gene expression. RRP1B interacts with TRIM28 and HP1α at regions.
Expression of chemokine receptors in A-498 cell line.
LY elicits hyperphosphorylation of Akt.
MTOR kinase inhibition–induced reactivation of AKT substrates is HER2 and PI3K dependent. mTOR kinase inhibition–induced reactivation of AKT substrates.
Effect of SFN on the total activity and protein expression of HDACs in JB6 P+ cells. Effect of SFN on the total activity and protein expression of HDACs.
Expression of anti-versican shRNA decreased breast cancer cell mammosphere and colony formation. Expression of anti-versican shRNA decreased breast cancer.
I3C reduces the level of Cdc25A protein in breast cancer cells.
D-GM3 promotes uPAR clustering on the cell surface and activates p38 MAPK. A, uPAR expression in cells was either knocked down by treatment with 4 independent.
Presentation transcript:

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. A, two erbB-2-overexpressing cancer cell lines (SKBr-3 and MDA-MB-453) and two cell lines expressing low levels of erbB-2 receptor (MDA-MB-468 and MDA-MB-231) were incubated with trastuzumab (1 μm) for 4 days. Cell lysates were prepared and immunoblotted with antibodies to phospho-Akt (p-Akt), Akt, phospho-MAPK (p-MAPK), MAPK, and tubulin as indicated to the right. Tubulin is shown as a loading control. The bracket at the right indicates p-MAPK. The relative intensity of phosphorylation of erk1 and erk2 varied among different cell lines. Molecular weights (in thousands) are shown to the left. B, the erbB-2-overexpressing cell line SKBr-3 was transfected with antisense (AS) or sense (S) ODNs or mock-transfected (M). After transfection, cells were incubated for an additional 72 h. Lysates were prepared and immunoblotted with antibodies as described in A. Molecular weights (in thousands) are shown to the left. Mauricio Cuello et al. Cancer Res 2001;61:4892-4900 ©2001 by American Association for Cancer Research